摘要
目的 :为临床肾移植患者他可莫司 (FK5 0 6 )的合理用药提供参考。方法 :采用微粒子酶免分析法对 2 0 6例肾移植患者进行血药浓度监测 ,并对其结果及疗效进行分析总结。结果 :为 2 0 6例肾移植患者监测了 1732例次FK5 0 6血药浓度 ,其中有效血药浓度范围内的有 917例次 ,占 5 2 .9% ;低于有效血药浓度的有 6 49例次 ,占 37.5 % ;高于有效血药浓度的有 16 6例次 ,占 9.6 %。结论 :为用药安全有效 ,应监测FK5 0 6血药浓度 。
OBJECTIVE To give some information for rationally administrating oral FK506 to renal transplant patients in clinic. METHODS The whole blood concentration of FK506 on 206 renal transplant patients was determined by microparticle eniyme immuno assay, the results and the therapeutic effect were studied. RESULTS Of 1732 cases in 206 renal transplant patients received FK506, the whole blood concentrations of 917 cases with effective level were accounted for 52.9%; and the whole blood concentrations of 649 cases were below effective level, accounting for 37.5%; while 84 cases whose whole blood concentrations were high effective level, accounting for 9.6%. CONCLUSIONS To be safe and effective for clinical use, it is important for renal transplant patients to monitor whole blood concentrations of FK506 with individualized drug adminstration.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2002年第3期147-149,共3页
Chinese Journal of Hospital Pharmacy
